Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420314 · ClinicalTrials.gov registry record · Phase 2
Pharmacological Ascorbate for Lung Cancer
A Phase 2 study, sponsored by Joseph J. Cullen, MD, FACS.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT02420314 is a Phase 2 study that has completed, run by Joseph J. Cullen, MD, FACS. The registered enrollment target is 55 participants.
The verdict
NCT02420314, a Phase 2 study, has completed, sponsored by Joseph J. Cullen, MD, FACS.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of non-small cell lung cancer (NSCLC) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Ascorbic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-04 |
| Est. Completion | 2022-08-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02420314
The ClinicalTrials.gov registry entry for NCT02420314 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joseph J. Cullen, MD, FACS, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT02420314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02420314 about?
NCT02420314 is a clinical study titled "Pharmacological Ascorbate for Lung Cancer". This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of non-small cell lung cancer (NSCLC) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.
What is the current status of trial NCT02420314?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2015-04. Estimated completion is 2022-08-27.
What interventions are being tested in trial NCT02420314?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Ascorbic Acid (DRUG).
Who is sponsoring clinical trial NCT02420314?
This trial is sponsored by Joseph J. Cullen, MD, FACS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.